Advertisement

Topics

Fibrocell to Host Conference Call and Webcast on Thursday, August 4, 2016 to Discuss Second Quarter 2016 Financial Results and Recent Operational Highlights

20:00 EDT 27 Jul 2016 | Globe Newswire

EXTON, Pa., July 28, 2016 (GLOBE NEWSWIRE) -- Fibrocell Science, Inc. (NASDAQ:FCSC) will report financial results for the second quarter ended June 30, 2016 and recent operational highlights on Thursday, August 4, 2016, before the open of the U.S. financial markets.  Fibrocell will also host a conference call and webcast at 8:30 a.m. EDT on the same day to discuss its financial results and operational highlights. A question-and-answer session will follow Fibrocell’s remarks.

To participate on the live call, please dial 888-428-9490 (domestic) or +1-719-785-1753 (international), and provide the conference code 2654515 five to ten minutes before the start of the call. The conference call will also be webcast live under the investor relations section of Fibrocell's website at www.fibrocell.com/investors/events and will be archived there for 30 days following the call. Please visit Fibrocell's website several minutes prior to the start of the broadcast to ensure adequate time for any software download that may be necessary.

About Fibrocell

Fibrocell is an autologous cell and gene therapy company translating personalized biologics into medical breakthroughs for diseases affecting the skin and connective tissue. Fibrocell’s most advanced orphan gene-therapy product candidate, FCX-007, has begun a Phase I/II trial for the treatment of recessive dystrophic epidermolysis bullosa (RDEB). Fibrocell is in pre-clinical development of FCX-013, its orphan gene-therapy product candidate for the treatment of linear scleroderma. In addition, Fibrocell has a third gene-therapy program in the research phase for the treatment of arthritis and related conditions. Fibrocell’s gene therapy portfolio is being developed in collaboration with Intrexon Corporation (NYSE:XON), a leader in synthetic biology.  For more information, visit www.fibrocell.com or follow us on Twitter at @Fibrocell.


 

Investor Relations Contact:
John Woolford
Westwicke Partners
443.213.0506 
john.woolford@westwicke.com

Primary Logo

NEXT ARTICLE

More From BioPortfolio on "Fibrocell to Host Conference Call and Webcast on Thursday, August 4, 2016 to Discuss Second Quarter 2016 Financial Results and Recent Operational Highlights"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Gene Therapy
Gene therapy is the use of DNA as a pharmaceutical agent to treat disease. It derives its name from the idea that DNA can be used to supplement or alter genes within an individual's cells as a therapy to treat disease. The most common form of gene th...

Biotherapeutics
The field encompassing therapeutic materials produced using biological means, including recombinant DNA technology. Biotherapeutics, also known as biotech drugs or biologics, are therapies derived from living organisms. By harnessing these living cells...